Floatz logo

Anti-Cd19/Cd22 Car-T Cells

MCL

Essen BiotechCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the MCL cohort.

Asset / SponsorPhaseRating
DOTATOC
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2CCC
Epcoritamab
Genmab
Phase 1/2CC
Promethazine
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2CC
Baff-R Car-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2CC
cd22 car-transduced t cells
Essen Biotech
Phase 1/2CC
Hmpl-760
Hutchmed
Phase 1CC
ANTI-CD47/CD19 BISPECIFIC MONOCLONAL ANTIBODY TG-1801
TG Therapeutics, Inc.
Phase 1CC
Gadobutrol
University Hospital, Bonn
D

Same molecule, other indications

Anti-Cd19/Cd22 Car-T Cells is also rated in:

Acute Lymphobkastic LeukemiaDormant
B
Indicative ·
57 / 100
View asset →
CAR T Cell TherapyDormant
B
Indicative ·
57 / 100
View asset →
Auto Stem Cell TransplantDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →